Compare 8x8 Inc (EGHT) vs Natera Inc. Common Stock (NTRA) Price & Performance

EGHT trades at $2.05, up 0.49% with a bullish technical signal despite bearish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.

EGHT presents a high-risk, high-reward opportunity with substantial upside to analyst targets but faces execution risks amid negative earnings. The stock's low price-to-sales ratio of 0.39 suggests undervaluation, though high debt levels and thin margins require careful monitoring. Positive momentum in AI adoption and client acquisitions could drive revaluation if profitability targets are met.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.